Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea

Combinations of compounds of formula (I)

• in which
• X represents S, N or O;
• Y represents N, S or O,
• where, if X represents S, then Y represents N;
• where, if X represents O, then Y represents N;
• Z represents CR4, O or NR4,
• where, if X represents N and Y represents N, then Z represents O;
• where, if X represents S, then Z represents CR4 or NR4
• R1 represents 5- or 6-membered heteroaryl, phenyl,
• where 5- to 6-membered heteroaryl may be substituted by 1 to 2 substituents independently of one another selected from the group of (C1-C4)-alkyl, (C1-C4)-alkoxy, halogen;
• where (C1-C4)-alkyl may be up to trisubstituted by halogen,
• where (C1-C4)-alkoxy may be up to trisubstituted by halogen,
• where phenyl may be substituted by 1 to 2 substituents independently of one another selected from the group of (C1-C4)-alkyl, (C3-C5)-cycloalkyl, (C1-C4)-alkoxy, cyano, hydroxy, halogen;
• where (C1-C4)-alkyl may be up to trisubstituted by halogen,
• R2 represents hydrogen, (C1-C4)-alkyl;
• where (C1-C4)-alkyl may be up to trisubstituted by halogen,
• or
• together with the carbon atom to which R2 is attached forms a (C3-C4)-cycloalkyl ring,
• R3 represents hydrogen, (C1-C4)-alkyl,
• where (C1-C4)-alkyl may be up to trisubstituted by halogen,
• R4 in CR4 represents hydrogen, (C1-C4)-alkyl, (C3-C4)-cycloalkyl, phenyl, halogen;
• where (C1-C4)-alkyl may be up to trisubstituted by halogen and phenyl may be substituted by halogen,
• in NR4 represents hydrogen, (C1-C4)-alkyl, (C3-C4)-cycloalkyl, phenyl;
• where (C1-C4)-alkyl may be up to trisubstituted by halogen and phenyl may be substituted by halogen,
• R5 represents hydrogen, (C1-C4)-alkyl, (C1-C4)-alkoxy, halogen,
• R6 represents a group of formula a), b), c), d), e), f) or g)
• where *** marks the attachment to the adjacent piperidine ring,
• where R7 represents hydrogen, (C1-C4)-alkyl, (C3-C4)-cycloalkyl, (C1-C4)-alkoxy, (C3-C4)-cycloalkoxy, phenyl,
• where (C1-C4)-alkyl may be substituted by (C3-C4)-cycloalkyl, (C1-C4)-alkoxy, (C3-C4)-cycloalkoxy and up to trisubstituted by halogen,
• where (C1-C4)-alkoxy may be substituted by (C3-C4)-cycloalkyl and up to trisubstituted by halogen,
• where (C3-C4)-cycloalkyl may be substituted by monofluoromethyl, difluoromethyl or trifluoromethyl and up to disubstituted by halogen,
• where (C1-C4)-alkoxy may be substituted by (C3-C4)-cycloalkyl and up to trisubstituted by halogen,
• where (C3-C4)-cycloalkyl may be mono- or disubstituted by halogen,
• where (C3-C4)-cycloalkoxy may be up to disubstituted by halogen,
• where R8 represents hydrogen or fluorine,
• where R9 represents hydrogen, (C1-C4)-alkyl, (C1-C4)-alkoxy, halogen;
• where (C1-C4)-alkyl may be substituted by (C1-C4)-alkoxy,
• n represents 0 or 1,
• m represents 0, 1 or 2,
• p represents 0, 1 or 2 and
• q represents 0, 1 or 2,
• and
• a noradrenaline reuptake inhibitor,
• and the salts, solvates and solvates of the salts thereof.